Cetera Investment Advisers Has $12.48 Million Holdings in Sanofi (NASDAQ:SNY)

Key Points

• Cetera Investment Advisers increased its holdings in Sanofi by 13.0%, owning 225,079 shares worth approximately $12.48 million at the end of the first quarter.
• Several institutional investors, including Brighton Jones LLC and CIBC Private Wealth Group LLC, significantly boosted their stakes in Sanofi during the fourth quarter, reflecting growing confidence in the stock.
• Sanofi's stock has a current market cap of $121.03 billion and an average analyst rating of "Buy" with a price target of $62.00.

Cetera Investment Advisers lifted its position in Sanofi (NASDAQ:SNY - Free Report) by 13.0% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 225,079 shares of the company's stock after acquiring an additional 25,941 shares during the period. Cetera Investment Advisers' holdings in Sanofi were worth $12,483,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Invesco Ltd. grew its position in Sanofi by 3.5% during the fourth quarter. Invesco Ltd. now owns 12,059,283 shares of the company's stock valued at $581,619,000 after purchasing an additional 408,752 shares in the last quarter. Bank of America Corp DE lifted its stake in Sanofi by 3.8% in the fourth quarter. Bank of America Corp DE now owns 12,017,140 shares of the company's stock valued at $579,587,000 after acquiring an additional 441,637 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in Sanofi by 88.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 10,843,682 shares of the company's stock valued at $522,991,000 after acquiring an additional 5,091,304 shares during the last quarter. Franklin Resources Inc. lifted its stake in Sanofi by 10.8% in the fourth quarter. Franklin Resources Inc. now owns 3,776,982 shares of the company's stock valued at $182,164,000 after acquiring an additional 369,530 shares during the last quarter. Finally, Nuveen Asset Management LLC lifted its stake in Sanofi by 1.0% in the fourth quarter. Nuveen Asset Management LLC now owns 3,676,224 shares of the company's stock valued at $177,304,000 after acquiring an additional 34,660 shares during the last quarter. 14.04% of the stock is owned by hedge funds and other institutional investors.

Sanofi Stock Performance

Sanofi stock traded up $1.11 during mid-day trading on Friday, hitting $46.75. 2,518,877 shares of the company's stock traded hands, compared to its average volume of 2,571,072. The firm has a 50 day simple moving average of $49.21 and a two-hundred day simple moving average of $52.09. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.37 and a quick ratio of 0.69. The stock has a market cap of $114.65 billion, a price-to-earnings ratio of 16.70, a P/E/G ratio of 1.12 and a beta of 0.48. Sanofi has a fifty-two week low of $44.73 and a fifty-two week high of $60.12.

Wall Street Analyst Weigh In

SNY has been the subject of a number of analyst reports. Morgan Stanley set a $56.00 target price on shares of Sanofi in a research note on Monday, June 2nd. BNP Paribas initiated coverage on shares of Sanofi in a research note on Tuesday, April 15th. They issued an "outperform" rating and a $65.00 target price for the company. Barclays reiterated an "overweight" rating on shares of Sanofi in a research note on Wednesday, July 2nd. Hsbc Global Res upgraded shares of Sanofi to a "strong-buy" rating in a research note on Monday, April 28th. Finally, Guggenheim restated a "buy" rating on shares of Sanofi in a research note on Tuesday, June 3rd. Three research analysts have rated the stock with a hold rating, three have issued a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $62.00.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.